



Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India

Mumbai, August 6th, 2014 - Sanofi in India announced today that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals (Emcure) for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range - comprising 4 brands namely Taxotere®, Jevtana®, Fludara® and Fasturtec®, Emcure will market and distribute these brands through its Specialty Unit..

Commenting on the partnership, **Dr. Shailesh Ayyangar, Vice President - South Asia and Managing Director - Sanofi India Limited and Sanofi – Synthelabo (India) Limited** said *"Sanofi is highly committed to the field of Oncology. Realizing that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies. Doctors and patients will now have access - 'under one roof' - to one of the most comprehensive and complementing Oncology portfolios in India. Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing Oncology business."*

Mr. Satish Mehta, Managing Director, Emcure Pharmaceuticals stated, *"We are delighted to be identified as the partner-of-choice by Sanofi in India ; and for being entrusted with such a prestigious global Oncology portfolio. We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions. We are extremely optimistic about its prospects and committed to creating a long-term partnership with Sanofi."*

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

In India, Sanofi is present since 1956.

For more information, please visit: www.sanofi.com or www.sanofi.in



About Emcure

Established in 1983, Emcure was born out of the vision to create a healthcare company with emphasis on technology driven products, and commitment to quality and excellence. This commitment has propelled the company from a successful domestic player to an emerging global player. The company today has world class manufacturing facilities spread across API, formulations and biotechnology. Many of these facilities have accreditations from global regulators including US FDA, UK MHRA etc. Emcure develops, manufactures and markets formulations under its own brands in the domestic market and in emerging markets like Asia, Africa, CIS, Latin America and the Middle East and North Africa. The company also supplies products to regulated markets of North America and Europe. Emcure is ranked among top 12 by IMS in the Indian Pharmaceutical industry.

Sanofi India Media Contacts:

Aparna THOMAS

Senior Director - Communications (South Asia) & Public Affairs (India)

Tel.: + (91) 22 2827 8169

aparna.thomas@sanofi.com

Ruchita MEHRA

Head – External Communications

Tel.: + (91) 22 2827 8233

ruchita.mehra@sanofi.com

References:

1. <http://timesofindia.indiatimes.com/india/1-million-new-cancer-cases-being-diagnosed-in-India-each-year-Study/articleshow/33610237.cms>